TEGOGLAS® BY ARKEMA

Tegoglas® RP40C

Cold-end coating of glass containers

Product data	
Active ingredient	Modified wax
Solid material content	Approx. 23.5%
Specific weight	1.0 g/cm³ (20° C)
Form	Dispersion
Colour	Cream-coloured
pH	Neutral to slightly alkaline

Properties

By using Tegoglas® RP40C, following benefits are achieved:

- Long-lasting protection of the glass surface
- Excellent dry scratch resistance
- Excellent wet scratch resistance
- Excellent wet smoothness after several treatments with alkaline solutions
- Excellent wet smoothness after sterilization and/or pasteurization processes
- Very good wet scratch resistance during the filling process in zones where the glass containers accumulate and are exposed to pressure
- Excellent protection during transportation
- Reduced glass fracture during filling and transportation
- Considerably reduced scuffing of the glass surface after transportation, filling, or other mechanical wear.

The basis for optimum performance of the cold-end coating is a hot-end coating with a tin oxide layer of 35 CTU min.

Tegoglas® RP40C is used as a cold-end coating agent on the following types of glass containers:

- Thin-walled, lightweight glass containers (non-returnable containers)
- Returnable glass containers
- Food jars (for fruit, vegetables, sausage, fish, etc.)
- Glass containers for hot-filling/re-cooling (water bath)
- Glass containers subject to extreme wear and tear during filling
- Glass containers to be pasteurised or sterilised

Product safety

The raw materials used for the manufacture of Tegoglas® RP40C are listed in the relevant §§ of the FDA. The waxes used in this formulation are listed on the European Positive list of additives authorized for plastic materials and articles intended to come into contact with foodstuffs.

Application

Tegoglas® RP40C is diluted with deionised or softened water and applied at the cold-end section by using a suitable spray system. If applied correctly, the resultant coating is virtually invisible.

A dilution ratio of 1:100 is usually recommended, but it can be varied between 0.5 and 2:100.
The Certincoat Dosing Unit is recommend for preparation.
When diluted with deionised or softened water, the Tegoglas® RP40C dilution has a pot life of several days. The pot life of cold-end dilutions is dependent on water quality.

Tegoglas® RP40C is suitable for coating containers that are 100°C to 150°C in temperature, preferably above 120°C

Labelling

We recommend the use of casein adhesives in connection with Tegoglas® RP40C.

Dispatch and storage

Packaging	Height mm	Depth mm	Width mm	Weight gross kg	Weight net kg
60 l non-returnable PE-Drums	635	390	340	63	60

Tegoglas® RP40C must be protected from frost during transport and storage. The shelf life is 2 years when the product is stored at a temperature between 5°C and 35°C in an unopened container.

Safety

Please refer to our health and safety data sheet for information on toxicity and ecology.

The information and advice contained in this data sheet is to the best of our knowledge and is provided without obligation.
We are not liable for any wrong advice or any advice we may have failed to give, unless otherwise agreed by the parties.

This data sheet becomes invalid as soon as a new edition has been published.

Arkema France - A French « société anonyme », registered with the Commercial and Companies Register of Nanterre (France) under number 319 632 790
4621E/09-2008/pdf - Add'/Glass coating - Photos: Arkema, Istock - Design Kythimie 01 47 49 56 60

The statements, technical information and recommendations contained herein are believed to be accurate as of the date hereof. Since the conditions and methods of use of the product and of the information referred to herein are beyond our control, ARKEMA expressly disclaims any and all liability as to any results obtained or arising from any use of the product or reliance on such information; NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED, IS MADE CONCERNING THE GOODS DESCRIBED OR THE INFORMATION PROVIDED HEREIN. The information provided herein relates only to the specific product designated and may not be applicable when such product is used in combination with other materials or in any process. The user should thoroughly test any application before commercialization. Nothing contained herein constitutes a license to practice under any patent and it should not be construed as an inducement to infringe any patent and the user is advised to take appropriate steps to be sure that any proposed use of the product will not result in patent infringement. See SDS for Health & Safety Considerations.
Arkema has implemented a Medical Policy regarding the use of Arkema products in Medical Devices applications that are in contact with the body or circulating bodily fluids (http://www.arkema.com/en/social-responsibility/responsible-product-management/medical-device-policy/index.html) Arkema has designated Medical grades to be used for such Medical Device applications. Products that have not been designated as Medical grades are not authorized by Arkema for use in Medical Device applications that are in contact with the body or circulating bodily fluids. In addition, Arkema strictly prohibits the use of any Arkema products in Medical Device applications that are implanted in the body or in contact with bodily fluids or tissues for greater than 30 days. The Arkema trademarks and the Arkema name shall not be used in conjunction with customers' medical devices, including without limitation, permanent or temporary implantable devices, and customers shall not represent to anyone else, that Arkema allows, endorses or permits the use of Arkema products in such medical devices.
It is the sole responsibility of the manufacturer of the medical device to determine the suitability (including biocompatibility) of all raw materials, products and components, including any medical grade Arkema products, in order to ensure that the final end-use product is safe for its end use; performs or functions as intended; and complies with all applicable legal and regulatory requirements (FDA or other national drug agencies) It is the sole responsibility of the manufacturer of the medical device to conduct all necessary tests and inspections and to evaluate the medical device under actual end-use requirements and to adequately advise and warn purchasers, users, and/or learned intermediaries (such as physicians) of pertinent risks and fulfill any postmarket surveillance obligations.
Any decision regarding the appropriateness of a particular Arkema material in a particular medical device should be based on the judgment of the manufacturer, seller, the competent authority, and the treating physician.

ARKEMA
INNOVATIVE CHEMISTRY

Headquarters: Arkema France
420, rue d'Estienne d'Orves
92705 Colombes Cedex – France
Tel.: 33 (0)1 49 00 79 92
Fax: 33 (0)1 49 00 77 30
arkema.com

tegoglas.com